Chinese Academy of Medical Sciences: Breast Neoplasms trials

The registry lists 52 Breast Neoplasms studies with Chinese Academy of Medical Sciences as lead sponsor. 6 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 31Phase 3 8Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerNot yet recruitingNCT05291910Phase 4
• Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruitingNCT05287308Not applicable
• Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant ReconstructionRecruitingNCT05045287Not applicable
• Radiotherapy for Extracranial Oligometastatic Breast CancerRecruitingNCT04646564Phase 3
• Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT04437160Phase 2
• A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast CancerNot yet recruitingNCT03854617Phase 2
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast CancerStatus unknownNCT01928680Phase 2Results posted
• HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BCStatus unknownNCT05566457Phase 2
• Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownNCT05546255Phase 2
• Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI TechnologyStatus unknownNCT05441098
• Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABCStatus unknownNCT05343117
• Neratinib Dose Escalation Regimen for HER2 Positive Early Breast CancerStatus unknownNCT05154396Phase 2
• Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast CancerStatus unknownNCT05089643Phase 2
• Characteristics and Treatment Trends of Young Breast Cancer in ChinaStatus unknownNCT05068115
• Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2
• Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABCStatus unknownNCT05000736
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast CancerStatus unknownNCT04289974
• Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast CancerStatus unknownNCT04194684Phase 2
• Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast CancerStatus unknownNCT04158505
• Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )Status unknownNCT04033172Phase 2
• Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCRStatus unknownNCT03947736
• A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast CancerStatus unknownNCT03939871Phase 2
• A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerStatus unknownNCT03933982Phase 2
• Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast CancerStatus unknownNCT03933319Phase 2
• Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast CancerStatus unknownNCT03923179Phase 2
• Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast CancerStatus unknownNCT03923166Phase 2
• The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair DeficiencyStatus unknownNCT03876886Phase 3
• Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerStatus unknownNCT03735082Phase 2
• Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast CancerCompletedNCT03535961Phase 2
• Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving SurgeryCompletedNCT03320421Not applicable
• S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast CancerStatus unknownNCT02947061Phase 2
• Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast CancerStatus unknownNCT02934828Phase 2
• Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer PatientsStatus unknownNCT02829008Phase 2
• The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With ChemotherapyStatus unknownNCT02771756Not applicable
• Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast CancerStatus unknownNCT02768415Phase 2
• Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer PatientsStatus unknownNCT02765373
• Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer PatientsStatus unknownNCT02646735Phase 2
• Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast CancerStatus unknownNCT02595138Phase 3
• Everolimus trIal for Advanced prememopausaL Breast Cancer PatientsStatus unknownNCT02313051Phase 2
• Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast CancerStatus unknownNCT02041338Phase 2
• Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer PatientsStatus unknownNCT01939054Phase 2
• Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast CancerStatus unknownNCT01492556Phase 2
• Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast CancerStatus unknownNCT01492543Phase 2
• Study of Aspirin and Exemestane as Adjuvant Treatment in Breast CancerStatus unknownNCT01431053Phase 2
• The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBCStatus unknownNCT01378533Phase 3
• Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer PatientsStatus unknownNCT01278810Phase 1
• Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast CancerStatus unknownNCT01276769Phase 2
• Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast CancerCompletedNCT01150513Phase 2/3
• Regimens Comparison for Breast Cancers of Positive Lymph NodesStatus unknownNCT01134523Phase 3
• Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive NodesTerminatedNCT00805597Phase 3
• A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast CancerCompletedNCT00793962Phase 3